| 哌加他尼钠的药理作用和临床评价 |
| |
| 引用本文： | 胡艳玲,史爱欣,傅得兴,胡欣. 哌加他尼钠的药理作用和临床评价[J]. 中国新药杂志, 2007, 16(7): 573-576 |
| |
| 作者姓名： | 胡艳玲 史爱欣 傅得兴 胡欣 |
| |
| 作者单位： | 1. 山东大学药学院药物分析研究所,济南,250012
2. 卫生部北京医院临床药理基地,北京,100730 |
| |
| 摘 要： | 哌加他尼钠（pegaptanib sodium，其注射剂商品名为Macugen）为选择性血管内皮生长因子（VEGF）抑制剂，美国FDA于2004年12月20日批准其用于治疗年龄相关性黄斑变性（AMD）。本品能减慢脉络膜新生血管的形成，降低病变血管的渗漏。临床研究表明，其治疗渗出性AMD疗效显著，且耐受性良好。现对其药理作用、药动学及临床评价及不良反应做一综述。
|
| 关 键 词： | 年龄相关性黄斑变性 哌加他尼钠 血管内皮生长因子 药理作用 临床评价 |
| 文章编号： | 1003-3734（2007）07-0573-04 |
| 收稿时间： | 2007-01-22 |
| 修稿时间： | 2007-01-22 |
Pharmacology and clinical evaluation of pegaptanib sodium |
| |
| HU Yan-ling,SHI Ai-xin,FU De-xing,HU Xin. Pharmacology and clinical evaluation of pegaptanib sodium[J]. Chinese Journal of New Drugs, 2007, 16(7): 573-576 |
| |
| Authors: | HU Yan-ling SHI Ai-xin FU De-xing HU Xin |
| |
| Affiliation: | 1.Institute of Pharmaceutical Analysis, College of Pharmacy, Shandong University, Jinan 250012, China ; 2. Clinical Pharmacology Base, Beijing Hospital, Beijing 100730, China |
| |
| Abstract: | Pegaptanib sodium is the first in a new class of ophthalmic preparations that selectively inhibits vascular endothelial growth factor(VEGF) for the treatment of neovascular(wet) age-related macular degeneration(AMD).Pegaptanib sodium acts by slowing the process of choroidal neovascularization(CNV) and minimizing vessel permeability.Clinical studies suggested that Macugen significantly prevented vision loss compared to sham treatment and was well tolerated.This paper reviews the pharmacology,pharmacokinetics and clinical evaluation of pegaptanib. |
| |
| Keywords: | age-related macular degeneration pegaptanib sodium vascular endothelial growth factor pharmacology clinical evaluation |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
| 点击此处可从《中国新药杂志》浏览原始摘要信息 |
